Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130493 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
A Phase 3 study of Parkinson's Disease, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT01130493 is a Phase 3 study of Parkinson's Disease that has completed, run by Impax Laboratories. The registered enrollment target is 110 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT01130493, a Phase 3 study of Parkinson's Disease, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
Conditions Studied
Interventions
- DRUG IPX066
- DRUG CLE
Study Locations (20)
Other
- Hôpital Gabriel Montpied-Service de Neurologie A- - Clermont-Ferrand
- Service de neurologie-Hôpital de la Timone- - Marseille
- Praxis für Neurologie, Psychiatrie und Psychotherapie Achim - Achim
- Praxis Dres. Bitter/Schumann - Bochum
- Klinikum rechts der Isar der Technischen Universität München - München
- Klinik für Neurologie, Stadtroda - Stadtroda
- RKU, Neurologische Klinik der Universität Ulm - Ulm
- Casa di Cura Villa Margherita - Arcugnano
Florida
- UM Movement Disorders Center - Miami
- Charlotte Neurological Services - Port Charlotte
- USF Parkinson's and Movement Disorders Center - Tampa
California
- Margolin Brain Institute - Fresno
- The Parkinson's Institute in Sunnyvale - Sunnyvale
New York
- Parkinson's Disease and Movement Disorders Center of Long Island - Commack
- Kingston Neurological Associates - Kingston
Michigan
- Quest Research Institute - Bingham Farms
Nevada
- University Health Systems - Las Vegas
Ohio
- University Neurology, Inc - Cincinnati
Virginia
- Sentara Neurological Associates - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130493
The ClinicalTrials.gov registry entry for NCT01130493 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (83% lower). The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which IPX066 is the first listed.
NCT01130493 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, California.
Frequently Asked Questions
What is clinical trial NCT01130493 about?
NCT01130493 is a clinical study titled "A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066". This is a study to compare the efficacy of IPX066 and CLE in subjects with advanced Parkinson's disease.
What is the current status of trial NCT01130493?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 110 participants. The study started on 2010-05. Estimated completion is 2012-01.
What conditions does trial NCT01130493 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01130493?
The interventions under investigation include: IPX066 (DRUG), CLE (DRUG).
Who is sponsoring clinical trial NCT01130493?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01130493 being conducted?
This trial has 20 study locations across California, Florida, Michigan, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.